Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers

Simon F. Shakar, Brian D Lowes, Joann Lindenfeld, Ronald Zolty, Marc Simon, Alastair D. Robertson, Michael R. Bristow, Eugene E. Wolfel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background Peak oxygen consumption (VO2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO2. We questioned the value of peak VO2 in predicting outcome in patients treated with β-blockers. Methods and results We reviewed the records of 127 patients who had peak VO2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO2 hi) and ≤14 ml·kg·min (VO2 lo). VO2 hi had 109 patients and VO2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO2 and left ventricular ejection fraction were lower in VO2 lo versus VO2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO2 lo versus 79% in VO2 hi (P=.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival. Conclusions Current peak VO2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalJournal of Cardiac Failure
Volume10
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Oxygen Consumption
Heart Failure
Heart Transplantation
Survival
Stroke Volume
Multivariate Analysis
Transplantation
Heart Rate

Keywords

  • Oxygen uptake
  • exercise
  • heart transplantation
  • prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers. / Shakar, Simon F.; Lowes, Brian D; Lindenfeld, Joann; Zolty, Ronald; Simon, Marc; Robertson, Alastair D.; Bristow, Michael R.; Wolfel, Eugene E.

In: Journal of Cardiac Failure, Vol. 10, No. 1, 01.01.2004, p. 15-20.

Research output: Contribution to journalArticle

Shakar, SF, Lowes, BD, Lindenfeld, J, Zolty, R, Simon, M, Robertson, AD, Bristow, MR & Wolfel, EE 2004, 'Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers', Journal of Cardiac Failure, vol. 10, no. 1, pp. 15-20. https://doi.org/10.1016/S1071-9164(03)00593-1
Shakar, Simon F. ; Lowes, Brian D ; Lindenfeld, Joann ; Zolty, Ronald ; Simon, Marc ; Robertson, Alastair D. ; Bristow, Michael R. ; Wolfel, Eugene E. / Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers. In: Journal of Cardiac Failure. 2004 ; Vol. 10, No. 1. pp. 15-20.
@article{bf319c0d7eda4408b8c51a1195fb8d63,
title = "Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers",
abstract = "Background Peak oxygen consumption (VO2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO2. We questioned the value of peak VO2 in predicting outcome in patients treated with β-blockers. Methods and results We reviewed the records of 127 patients who had peak VO2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO2 hi) and ≤14 ml·kg·min (VO2 lo). VO2 hi had 109 patients and VO2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO2 and left ventricular ejection fraction were lower in VO2 lo versus VO2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8{\%} versus 21±9{\%}, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94{\%} in VO2 lo versus 79{\%} in VO2 hi (P=.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival. Conclusions Current peak VO2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.",
keywords = "Oxygen uptake, exercise, heart transplantation, prognosis",
author = "Shakar, {Simon F.} and Lowes, {Brian D} and Joann Lindenfeld and Ronald Zolty and Marc Simon and Robertson, {Alastair D.} and Bristow, {Michael R.} and Wolfel, {Eugene E.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/S1071-9164(03)00593-1",
language = "English (US)",
volume = "10",
pages = "15--20",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Peak oxygen consumption and outcome in heart failure patients chronically treated with β-blockers

AU - Shakar, Simon F.

AU - Lowes, Brian D

AU - Lindenfeld, Joann

AU - Zolty, Ronald

AU - Simon, Marc

AU - Robertson, Alastair D.

AU - Bristow, Michael R.

AU - Wolfel, Eugene E.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background Peak oxygen consumption (VO2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO2. We questioned the value of peak VO2 in predicting outcome in patients treated with β-blockers. Methods and results We reviewed the records of 127 patients who had peak VO2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO2 hi) and ≤14 ml·kg·min (VO2 lo). VO2 hi had 109 patients and VO2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO2 and left ventricular ejection fraction were lower in VO2 lo versus VO2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO2 lo versus 79% in VO2 hi (P=.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival. Conclusions Current peak VO2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.

AB - Background Peak oxygen consumption (VO2) is an important criterion for listing patients for cardiac transplantation. β-Blockers improve survival without affecting peak VO2. We questioned the value of peak VO2 in predicting outcome in patients treated with β-blockers. Methods and results We reviewed the records of 127 patients who had peak VO2 measured at baseline and were subsequently treated with β-blockers for at least 3 months. We divided the patients into 2 groups with peak oxygen consumption >14 (VO2 hi) and ≤14 ml·kg·min (VO2 lo). VO2 hi had 109 patients and VO2 lo had 18 patients. The combined end-point of death or cardiac transplantation was compared between groups. Mean peak VO2 and left ventricular ejection fraction were lower in VO2 lo versus VO2 hi: 12.4±1.4 ml·kg·min versus 19.1±3.9 ml·kg·min and 17±8% versus 21±9%, respectively. At 30 months, the percentage of patients who did not reach the combined end-point was 94% in VO2 lo versus 79% in VO2 hi (P=.47). In multivariate analysis, only changes in heart rate and LVEF from baseline to follow-up were predictive of survival. Conclusions Current peak VO2 cutoff does not predict survival without transplantation of patients who tolerate chronic treatment with β-blockers.

KW - Oxygen uptake

KW - exercise

KW - heart transplantation

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=3042732499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042732499&partnerID=8YFLogxK

U2 - 10.1016/S1071-9164(03)00593-1

DO - 10.1016/S1071-9164(03)00593-1

M3 - Article

VL - 10

SP - 15

EP - 20

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 1

ER -